SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001328143-21-000065
Filing Date
2021-06-11
Accepted
2021-06-11 16:00:57
Documents
12
Period of Report
2021-06-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K adms-20210609.htm   iXBRL 8-K 32325
  Complete submission text file 0001328143-21-000065.txt   174481

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adms-20210609.xsd EX-101.SCH 1914
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adms-20210609_lab.xml EX-101.LAB 26042
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adms-20210609_pre.xml EX-101.PRE 14071
5 EXTRACTED XBRL INSTANCE DOCUMENT adms-20210609_htm.xml XML 10978
Mailing Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

IRS No.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36399 | Film No.: 211011205
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences